{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T15:02:33Z","timestamp":1789830153323,"version":"4.0.1"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T00:00:00Z","timestamp":1789776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T00:00:00Z","timestamp":1789776000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Divers"],"DOI":"10.1007\/s11030-026-11713-0","type":"journal-article","created":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T14:15:30Z","timestamp":1789827330000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Structure-based drug repurposing and in vitro evaluation of VAV2-associated candidates for suppression of macrophage foam-cell formation in atherosclerosis"],"prefix":"10.1007","author":[{"given":"Prerna","family":"Bansal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4318-9483","authenticated-orcid":false,"given":"Kamna","family":"Srivastava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,19]]},"reference":[{"issue":"13 Suppl","key":"11713_CR1","doi-asserted-by":"publisher","first-page":"1996","DOI":"10.1016\/S0735-1097(24)03986-X","volume":"83","author":"B Chong","year":"2024","unstructured":"Chong B, Jayabaskaran J, Kueh MTW et al (2024) The global burden of cardiovascular diseases over the next 30 years: predictions from the past 30 years. J Am Coll Cardiol 83(13 Suppl):1996. https:\/\/doi.org\/10.1016\/S0735-1097(24)03986-X","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"11713_CR2","doi-asserted-by":"publisher","first-page":"11","DOI":"10.5334\/gh.1288","volume":"19","author":"M Di Cesare","year":"2024","unstructured":"Di Cesare M, Perel P, Taylor S et al (2024) The heart of the world. Global Heart 19(1):11. https:\/\/doi.org\/10.5334\/gh.1288","journal-title":"Global Heart"},{"issue":"2","key":"11713_CR3","doi-asserted-by":"publisher","first-page":"169","DOI":"10.2991\/jegh.k.201217.001","volume":"11","author":"U Ralapanawa","year":"2021","unstructured":"Ralapanawa U, Sivakanesan R (2021) Epidemiology and the magnitude of coronary artery disease and acute coronary syndrome: a narrative review. J Epidemiol Global Health 11(2):169\u2013177. https:\/\/doi.org\/10.2991\/jegh.k.201217.001","journal-title":"J Epidemiol Global Health"},{"issue":"3","key":"11713_CR4","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.micron.2005.10.007","volume":"37","author":"YV Bobryshev","year":"2006","unstructured":"Bobryshev YV (2006) Monocyte recruitment and foam cell formation in atherosclerosis. Micron 37(3):208\u2013222. https:\/\/doi.org\/10.1016\/j.micron.2005.10.007","journal-title":"Micron"},{"issue":"10","key":"11713_CR5","doi-asserted-by":"publisher","first-page":"e56","DOI":"10.1161\/CIR.0000000000000659","volume":"139","author":"EJ Benjamin","year":"2019","unstructured":"Benjamin EJ, Muntner P, Alonso A et al (2019) Heart disease and stroke statistics\u2009\u2013\u20092019 update: a report from the American Heart Association. Circulation 139(10):e56\u2013e528. https:\/\/doi.org\/10.1161\/CIR.0000000000000659","journal-title":"Circulation"},{"issue":"3","key":"11713_CR6","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.ihj.2019.04.007","volume":"71","author":"EA Enas","year":"2019","unstructured":"Enas EA, Varkey B, Dharmarajan TS, Pare G, Bahl VK (2019) Lipoprotein(a): an underrecognized genetic risk factor for malignant coronary artery disease in young Indians. Indian Heart J 71(3):184\u2013198. https:\/\/doi.org\/10.1016\/j.ihj.2019.04.007","journal-title":"Indian Heart J"},{"key":"11713_CR7","doi-asserted-by":"publisher","first-page":"100156","DOI":"10.1016\/j.lansea.2023.100156","volume":"12","author":"A Kalra","year":"2023","unstructured":"Kalra A, Jose AP, Prabhakaran P et al (2023) The burgeoning cardiovascular disease epidemic in Indians - perspectives on contextual factors and potential solutions. Lancet Reg Health-Southeast Asia 12:100156. https:\/\/doi.org\/10.1016\/j.lansea.2023.100156","journal-title":"Lancet Reg Health-Southeast Asia"},{"key":"11713_CR8","doi-asserted-by":"publisher","first-page":"4579","DOI":"10.1007\/s11030-024-11063-9","volume":"29","author":"SS Singhal nee Shelly Aggarwal","year":"2025","unstructured":"Singhal nee Shelly Aggarwal SS, Kaur D, Saluja D, Srivastava K (2025) Repurposed drugs as PCSK9-LDLR disruptors for lipid lowering and cardiovascular disease therapeutics. Mol Diversity 29:4579\u20134593. https:\/\/doi.org\/10.1007\/s11030-024-11063-9","journal-title":"Mol Diversity"},{"issue":"10","key":"11713_CR9","doi-asserted-by":"publisher","first-page":"2076","DOI":"10.1016\/j.drudis.2019.06.014","volume":"24","author":"V Parvathaneni","year":"2019","unstructured":"Parvathaneni V, Kulkarni NS, Muth A, Gupta V (2019) Drug repurposing: a promising tool to accelerate the drug discovery process. Drug Discov Today 24(10):2076\u20132085. https:\/\/doi.org\/10.1016\/j.drudis.2019.06.014","journal-title":"Drug Discovery Today"},{"issue":"2","key":"11713_CR10","doi-asserted-by":"publisher","first-page":"100071","DOI":"10.1016\/j.aichem.2024.100071","volume":"2","author":"A Singh","year":"2024","unstructured":"Singh A (2024) Artificial intelligence for drug repurposing against infectious diseases. Artif Intell Chem 2(2):100071. https:\/\/doi.org\/10.1016\/j.aichem.2024.100071","journal-title":"Artif Intell Chem"},{"key":"11713_CR11","doi-asserted-by":"publisher","first-page":"114239","DOI":"10.1016\/j.ejmech.2022.114239","volume":"234","author":"Y Hua","year":"2022","unstructured":"Hua Y, Dai X, Xu Y et al (2022) Drug repositioning: progress and challenges in drug discovery for various diseases. Eur J Med Chem 234:114239. https:\/\/doi.org\/10.1016\/j.ejmech.2022.114239","journal-title":"Eur J Med Chem"},{"issue":"12","key":"11713_CR12","doi-asserted-by":"publisher","first-page":"2190","DOI":"10.3390\/medicina59122190","volume":"59","author":"C Pu\u0219ca\u0219u","year":"2023","unstructured":"Pu\u0219ca\u0219u C, Zanfirescu A, Negre\u0219 S, \u0218eremet OC (2023) Exploring the multifaceted potential of sildenafil in medicine. Medicina 59(12):2190. https:\/\/doi.org\/10.3390\/medicina59122190","journal-title":"Medicina"},{"issue":"4","key":"11713_CR13","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.ijantimicag.2010.05.003","volume":"36","author":"K Mazumdar","year":"2010","unstructured":"Mazumdar K, Kumar KA, Dutta NK (2010) Potential role of the cardiovascular non-antibiotic (helper compound) amlodipine in the treatment of microbial infections: scope and hope for the future. Int J Antimicrob Agents 36(4):295\u2013302. https:\/\/doi.org\/10.1016\/j.ijantimicag.2010.05.003","journal-title":"Int J Antimicrob Agents"},{"issue":"1","key":"11713_CR14","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/s41467-019-13940-6","volume":"11","author":"TP Sheahan","year":"2020","unstructured":"Sheahan TP, Sims AC, Leist SR et al (2020) Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun 11(1):222. https:\/\/doi.org\/10.1038\/s41467-019-13940-6","journal-title":"Nat Commun"},{"issue":"9","key":"11713_CR15","doi-asserted-by":"publisher","first-page":"857","DOI":"10.3390\/biology10090857","volume":"10","author":"S Rodr\u00edguez-Fdez","year":"2021","unstructured":"Rodr\u00edguez-Fdez S, Lorenzo-Mart\u00edn LF, Fabbiano S, Menacho-M\u00e1rquez M, Sauzeau V, Dosil M, Bustelo XR (2021) New functions of Vav family proteins in cardiovascular biology, skeletal muscle, and the nervous system. Biology 10(9):857. https:\/\/doi.org\/10.3390\/biology10090857","journal-title":"Biology"},{"issue":"12","key":"11713_CR16","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1194\/jlr.M094771","volume":"60","author":"R Huang","year":"2019","unstructured":"Huang R, Guo G, Lu L et al (2019) The three members of the Vav family proteins form complexes that concur to foam cell formation and atherosclerosis. J Lipid Res 60(12):2006\u20132019. https:\/\/doi.org\/10.1194\/jlr.M094771","journal-title":"J Lipid Res"},{"issue":"1","key":"11713_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0898-6568(03)00110-4","volume":"16","author":"I Hornstein","year":"2004","unstructured":"Hornstein I, Alcover A, Katzav S (2004) Vav proteins, masters of the world of cytoskeleton organization. Cell Signal 16(1):1\u201311. https:\/\/doi.org\/10.1016\/S0898-6568(03)00110-4","journal-title":"Cell Signal"},{"issue":"3","key":"11713_CR18","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1091\/mbc.E06-09-0877","volume":"18","author":"V Sauzeau","year":"2007","unstructured":"Sauzeau V, Jerkic M, Lopez-Novoa JM, Bustelo XR (2007) Loss of Vav2 proto-oncogene causes tachycardia and cardiovascular disease in mice. Mol Biol Cell 18(3):943\u2013952. https:\/\/doi.org\/10.1091\/mbc.E06-09-0877","journal-title":"Mol Biol Cell"},{"issue":"1","key":"11713_CR19","doi-asserted-by":"publisher","first-page":"12752","DOI":"10.1038\/s41598-022-16883-z","volume":"12","author":"Y Zhang","year":"2022","unstructured":"Zhang Y, Yang X, Liu Y et al (2022) Vav2 is a novel APP-interacting protein that regulates APP protein level. Sci Rep 12(1):12752. https:\/\/doi.org\/10.1038\/s41598-022-16883-z","journal-title":"Sci Rep"},{"issue":"9","key":"11713_CR20","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1161\/ATVBAHA.113.301414","volume":"33","author":"SO Rahaman","year":"2013","unstructured":"Rahaman SO, Li W, Silverstein RL (2013) Vav guanine nucleotide exchange factors regulate atherosclerotic lesion development in mice. Arterioscler Thromb Vasc Biol 33(9):2053\u20132057. https:\/\/doi.org\/10.1161\/ATVBAHA.113.301414","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"1","key":"11713_CR21","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1172\/JCI38356","volume":"120","author":"V Sauzeau","year":"2010","unstructured":"Sauzeau V, Sevilla MA, Montero MJ, Bustelo XR (2010) The Rho\/Rac exchange factor Vav2 controls nitric oxide-dependent responses in mouse vascular smooth muscle cells. J Clin Invest 120(1):315\u2013330. https:\/\/doi.org\/10.1172\/JCI38356","journal-title":"J Clin Invest"},{"issue":"1","key":"11713_CR22","doi-asserted-by":"publisher","first-page":"41875","DOI":"10.1038\/srep41875","volume":"7","author":"N Perretta-Tejedor","year":"2017","unstructured":"Perretta-Tejedor N, Fern\u00e1ndez-Mateos J, Garc\u00eda-Ortiz L et al (2017) Association of VAV2 and VAV3 polymorphisms with cardiovascular risk factors. Sci Rep 7(1):41875. https:\/\/doi.org\/10.1038\/srep41875","journal-title":"Sci Rep"},{"issue":"4","key":"11713_CR23","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1038\/s41401-023-01217-0","volume":"45","author":"XX Li","year":"2024","unstructured":"Li XX, Chen ZD, Sun XJ, Yang YQ, Jin H, Liu NF (2024) Empagliflozin ameliorates vascular calcification in diabetic mice through inhibiting Bhlhe40-dependent NLRP3 inflammasome activation. Acta Pharmacol Sin 45(4):751\u2013764. https:\/\/doi.org\/10.1038\/s41401-023-01217-0","journal-title":"Acta Pharmacol Sin"},{"issue":"6","key":"11713_CR24","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1111\/bph.16001","volume":"180","author":"Z On\u00f3di","year":"2023","unstructured":"On\u00f3di Z, Koch S, Rubinstein J, Ferdinandy P, Varga ZV (2023) Drug repurposing for cardiovascular diseases: new targets and indications for probenecid. Br J Pharmacol 180(6):685\u2013700. https:\/\/doi.org\/10.1111\/bph.16001","journal-title":"Br J Pharmacol"},{"issue":"7873","key":"11713_CR25","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1038\/s41586-021-03819-2","volume":"596","author":"J Jumper","year":"2021","unstructured":"Jumper J, Evans R, Pritzel A et al (2021) Highly accurate protein structure prediction with AlphaFold. Nature 596(7873):583\u2013589. https:\/\/doi.org\/10.1038\/s41586-021-03819-2","journal-title":"Nature"},{"key":"11713_CR26","doi-asserted-by":"publisher","first-page":"102526","DOI":"10.1016\/j.sbi.2022.102526","volume":"78","author":"N Borkakoti","year":"2023","unstructured":"Borkakoti N, Thornton JM (2023) AlphaFold2 protein structure prediction: implications for drug discovery. Curr Opin Struct Biol 78:102526. https:\/\/doi.org\/10.1016\/j.sbi.2022.102526","journal-title":"Curr Opin Struct Biol"},{"issue":"D1","key":"11713_CR27","doi-asserted-by":"publisher","first-page":"D1074","DOI":"10.1093\/nar\/gkx1037","volume":"46","author":"DS Wishart","year":"2018","unstructured":"Wishart DS, Feunang YD, Guo AC et al (2018) DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res 46(D1):D1074\u2013D1082. https:\/\/doi.org\/10.1093\/nar\/gkx1037","journal-title":"Nucleic Acids Res"},{"key":"11713_CR28","unstructured":"ChemDiv Inc (2024) ChemDiv compound library. https:\/\/www.chemdiv.com. Accessed 15 Mar 2024"},{"key":"11713_CR29","doi-asserted-by":"publisher","unstructured":"Douguet D (2023) Structures of FDA-approved drugs and their active metabolites and data sets of experimental PD and PK properties (e-Drug3D_2083). https:\/\/doi.org\/10.5281\/zenodo.12706005. Zenodo","DOI":"10.5281\/zenodo.12706005"},{"key":"11713_CR30","unstructured":"Selleck Chemicals LLC (2024) Selleck Chemicals compound library. https:\/\/www.selleckchem.com."},{"issue":"D1","key":"11713_CR31","doi-asserted-by":"publisher","first-page":"D1516","DOI":"10.1093\/nar\/gkae1059","volume":"53","author":"S Kim","year":"2025","unstructured":"Kim S, Chen J, Cheng T et al (2025) PubChem 2025 update. Nucleic Acids Res 53(D1):D1516\u2013D1525. https:\/\/doi.org\/10.1093\/nar\/gkae1059","journal-title":"Nucleic Acids Res"},{"key":"11713_CR32","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/1758-2946-3-33","volume":"3","author":"NM O\u2019Boyle","year":"2011","unstructured":"O\u2019Boyle NM, Banck M, James CA, Morley C, Vandermeersch T, Hutchison GR (2011) Open Babel: an open chemical toolbox. J Cheminform 3:33. https:\/\/doi.org\/10.1186\/1758-2946-3-33","journal-title":"J Cheminform"},{"issue":"1\u20133","key":"11713_CR33","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/S0169-409X(96)00423-1","volume":"23","author":"CA Lipinski","year":"1997","unstructured":"Lipinski CA, Lombardo F, Dominy BW, Feeney PJ (1997) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 23(1\u20133):3\u201325. https:\/\/doi.org\/10.1016\/S0169-409X(96)00423-1","journal-title":"Adv Drug Deliv Rev"},{"issue":"8","key":"11713_CR34","doi-asserted-by":"publisher","first-page":"3891","DOI":"10.1021\/acs.jcim.1c00203","volume":"61","author":"J Eberhardt","year":"2021","unstructured":"Eberhardt J, Santos-Martins D, Tillack AF, Forli S (2021) AutoDock Vina 1.2.0: new docking methods, expanded force field, and python bindings. J Chem Inf Model 61(8):3891\u20133898. https:\/\/doi.org\/10.1021\/acs.jcim.1c00203","journal-title":"J Chem Inf Model"},{"key":"11713_CR35","doi-asserted-by":"publisher","first-page":"42717","DOI":"10.1038\/srep42717","volume":"7","author":"A Daina","year":"2017","unstructured":"Daina A, Michielin O, Zoete V (2017) SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci Rep 7:42717. https:\/\/doi.org\/10.1038\/srep42717","journal-title":"Sci Rep"},{"key":"11713_CR36","doi-asserted-by":"publisher","first-page":"1360226","DOI":"10.3389\/fphar.2024.1360226","volume":"15","author":"D Gheidari","year":"2024","unstructured":"Gheidari D, Mehrdad M, Hoseini F (2024) Virtual screening, molecular docking, MD simulation studies, DFT calculations, ADMET, and drug likeness of Diaza-adamantane as potential MAPKERK inhibitors. Front Pharmacol 15:1360226. https:\/\/doi.org\/10.3389\/fphar.2024.1360226","journal-title":"Front Pharmacol"},{"issue":"9","key":"11713_CR37","doi-asserted-by":"publisher","first-page":"4066","DOI":"10.1021\/acs.jmedchem.5b00104","volume":"58","author":"DEV Pires","year":"2015","unstructured":"Pires DEV, Blundell TL, Ascher DB (2015) pkCSM: predicting small-molecule pharmacokinetic and toxicity properties using graph-based signatures. J Med Chem 58(9):4066\u20134072. https:\/\/doi.org\/10.1021\/acs.jmedchem.5b00104","journal-title":"J Med Chem"},{"key":"11713_CR38","doi-asserted-by":"publisher","DOI":"10.5281\/zenodo.10560024","author":"M Abraham","year":"2024","unstructured":"Abraham M, Alekseenko A, Bergh C et al (2024) GROMACS 2023.4 Manual. Zenodo. https:\/\/doi.org\/10.5281\/zenodo.10560024","journal-title":"Zenodo"},{"issue":"10","key":"11713_CR39","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1002\/jcc.21287","volume":"30","author":"BR Brooks","year":"2009","unstructured":"Brooks BR, Brooks CL III, Mackerell AD Jr et al (2009) CHARMM: the biomolecular simulation program. J Comput Chem 30(10):1545\u20131614. https:\/\/doi.org\/10.1002\/jcc.21287","journal-title":"J Comput Chem"},{"issue":"11","key":"11713_CR40","doi-asserted-by":"publisher","first-page":"2359","DOI":"10.1002\/jcc.21816","volume":"32","author":"V Zoete","year":"2011","unstructured":"Zoete V, Cuendet MA, Grosdidier A, Michielin O (2011) SwissParam: a fast force field generation tool for small organic molecules. J Comput Chem 32(11):2359\u20132368. https:\/\/doi.org\/10.1002\/jcc.21816","journal-title":"J Comput Chem"},{"issue":"12","key":"11713_CR41","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1002\/(SICI)1096-987X(199709)18:12<1463::AID-JCC4>3.0.CO;2-H","volume":"18","author":"B Hess","year":"1997","unstructured":"Hess B, Bekker H, Berendsen HJC, Fraaije JGEM (1997) LINCS: a linear constraint solver for molecular simulations. J Comput Chem 18(12):1463\u20131472. https:\/\/doi.org\/10.1002\/(SICI)1096-987X(199709)18:12%3C1463::AID-JCC4%3E3.0.CO;2-H","journal-title":"J Comput Chem"},{"issue":"1","key":"11713_CR42","doi-asserted-by":"publisher","first-page":"4405","DOI":"10.1038\/s41598-019-40621-7","volume":"9","author":"M Shahbaaz","year":"2019","unstructured":"Shahbaaz M, Nkaule A, Christoffels A (2019) Designing novel possible kinase inhibitor derivatives as therapeutics against Mycobacterium tuberculosis: an in silico study. Sci Rep 9(1):4405. https:\/\/doi.org\/10.1038\/s41598-019-40621-7","journal-title":"Sci Rep"},{"issue":"5\u20136","key":"11713_CR43","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1080\/10799893.2018.1564150","volume":"38","author":"Y Bao","year":"2018","unstructured":"Bao Y, Zhou L, Dai D, Zhu X, Hu Y, Qiu Y (2018) Discover potential inhibitors for PFKFB3 using 3D-QSAR, virtual screening, molecular docking and molecular dynamics simulation. J Recept Signal Transduction 38(5\u20136):413\u2013431. https:\/\/doi.org\/10.1080\/10799893.2018.1564150","journal-title":"J Recept Signal Transduction"},{"issue":"2","key":"11713_CR44","doi-asserted-by":"publisher","first-page":"e1298","DOI":"10.1002\/wcms.1298","volume":"7","author":"S Yuan","year":"2017","unstructured":"Yuan S, Chan HCS, Hu Z (2017) Using PyMOL as a platform for computational drug design. Wiley Interdisciplinary Reviews: Comput Mol Sci 7(2):e1298. https:\/\/doi.org\/10.1002\/wcms.1298","journal-title":"Wiley Interdisciplinary Reviews: Comput Mol Sci"},{"issue":"16","key":"11713_CR45","doi-asserted-by":"publisher","first-page":"9478","DOI":"10.1021\/acs.chemrev.9b00055","volume":"119","author":"E Wang","year":"2019","unstructured":"Wang E, Sun H, Wang J, Wang Z, Liu H, Zhang JZH, Hou T (2019) End-point binding free energy calculation with MM\/PBSA and MM\/GBSA: strategies and applications in drug design. Chem Rev 119(16):9478\u20139508. https:\/\/doi.org\/10.1021\/acs.chemrev.9b00055","journal-title":"Chem Rev"},{"issue":"10","key":"11713_CR46","doi-asserted-by":"publisher","first-page":"6281","DOI":"10.1021\/acs.jctc.1c00645","volume":"17","author":"MS Vald\u00e9s-Tresanco","year":"2021","unstructured":"Vald\u00e9s-Tresanco MS, Vald\u00e9s-Tresanco ME, Valiente PA, Moreno E (2021) gmx_MMPBSA: a new tool to perform end-state free energy calculations with GROMACS. J Chem Theory Comput 17(10):6281\u20136291. https:\/\/doi.org\/10.1021\/acs.jctc.1c00645","journal-title":"J Chem Theory Comput"},{"issue":"9","key":"11713_CR47","doi-asserted-by":"publisher","first-page":"3314","DOI":"10.1021\/ct300418h","volume":"8","author":"BR Miller III","year":"2012","unstructured":"Miller BR III, McGee TD Jr, Swails JM, Homeyer N, Gohlke H, Roitberg AE (2012) MMPBSA.py: an efficient program for end-state free energy calculations. J Chem Theory Comput 8(9):3314\u20133321. https:\/\/doi.org\/10.1021\/ct300418h","journal-title":"J Chem Theory Comput"},{"issue":"14","key":"11713_CR48","doi-asserted-by":"publisher","first-page":"10141","DOI":"10.1074\/jbc.275.14.10141","volume":"275","author":"K Abe","year":"2000","unstructured":"Abe K, Rossman KL, Liu B et al (2000) Vav2 is an activator of Cdc42, Rac1, and RhoA. J Biol Chem 275(14):10141\u201310149. https:\/\/doi.org\/10.1074\/jbc.275.14.10141","journal-title":"J Biol Chem"},{"issue":"2","key":"11713_CR49","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.cell.2009.12.033","volume":"140","author":"B Yu","year":"2010","unstructured":"Yu B, Martins IRS, Li P et al (2010) Structural and energetic mechanisms of cooperative autoinhibition and activation of Vav1. Cell 140(2):246\u2013256. https:\/\/doi.org\/10.1016\/j.cell.2009.12.033","journal-title":"Cell"},{"issue":"6","key":"11713_CR50","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1038\/nsmb.1428","volume":"15","author":"P Li","year":"2008","unstructured":"Li P, Martins IRS, Amarasinghe GK, Rosen MK (2008) Internal dynamics control activation and activity of the autoinhibited Vav DH domain. Nat Struct Mol Biol 15(6):613\u2013618. https:\/\/doi.org\/10.1038\/nsmb.1428","journal-title":"Nat Struct Mol Biol"},{"issue":"18","key":"11713_CR51","doi-asserted-by":"publisher","first-page":"1939","DOI":"10.1007\/s40265-018-1026-z","volume":"78","author":"SM Hoy","year":"2018","unstructured":"Hoy SM (2018) Talazoparib: first global approval. Drugs 78(18):1939\u20131946. https:\/\/doi.org\/10.1007\/s40265-018-1026-z","journal-title":"Drugs"},{"issue":"12","key":"11713_CR52","doi-asserted-by":"publisher","first-page":"2735","DOI":"10.1158\/1535-7163.MCT-17-0365","volume":"16","author":"SH Kizilbash","year":"2017","unstructured":"Kizilbash SH, Gupta SK, Chang K et al (2017) Restricted delivery of talazoparib across the blood\u2013brain barrier limits the sensitizing effects of PARP inhibition on temozolomide therapy in glioblastoma. Mol Cancer Ther 16(12):2735\u20132746. https:\/\/doi.org\/10.1158\/1535-7163.MCT-17-0365","journal-title":"Mol Cancer Ther"},{"issue":"3","key":"11713_CR53","doi-asserted-by":"publisher","first-page":"e35675","DOI":"10.7759\/cureus.35675","volume":"15","author":"M Sakellakis","year":"2023","unstructured":"Sakellakis M, Zakopoulou R (2023) Current status of tivozanib in the treatment of patients with advanced renal cell carcinoma. Cureus 15(3):e35675. https:\/\/doi.org\/10.7759\/cureus.35675","journal-title":"Cureus"},{"issue":"3B","key":"11713_CR54","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/0002-9343(88)90193-3","volume":"84","author":"HF Schran","year":"1988","unstructured":"Schran HF, Jaffe JM, Gonasun LM (1988) Clinical pharmacokinetics of isradipine. Am J Med 84(3B):80\u201389. https:\/\/doi.org\/10.1016\/0002-9343(88)90193-3","journal-title":"Am J Med"},{"issue":"3","key":"11713_CR55","doi-asserted-by":"publisher","first-page":"210","DOI":"10.3109\/13697130903568542","volume":"13","author":"TJ De Villiers","year":"2010","unstructured":"De Villiers TJ (2010) Bazedoxifene: a novel selective estrogen receptor modulator for postmenopausal osteoporosis. Climacteric 13(3):210\u2013218. https:\/\/doi.org\/10.3109\/13697130903568542","journal-title":"Climacteric"},{"issue":"10","key":"11713_CR56","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1007\/s40265-018-0939-x","volume":"78","author":"YY Syed","year":"2018","unstructured":"Syed YY (2018) Anlotinib: first global approval. Drugs 78(10):1057\u20131062. https:\/\/doi.org\/10.1007\/s40265-018-0939-x","journal-title":"Drugs"},{"issue":"9","key":"11713_CR57","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1345\/aph.1E615","volume":"39","author":"JB Leslie","year":"2005","unstructured":"Leslie JB (2005) Alvimopan for the management of postoperative ileus. Ann Pharmacother 39(9):1502\u20131510. https:\/\/doi.org\/10.1345\/aph.1E615","journal-title":"Ann Pharmacother"},{"key":"11713_CR58","doi-asserted-by":"publisher","first-page":"2405","DOI":"10.2147\/DDDT.S153719","volume":"13","author":"GJ Connett","year":"2019","unstructured":"Connett GJ (2019) Lumacaftor-ivacaftor in the treatment of cystic fibrosis: design, development and place in therapy. Drug Des Devel Ther 13:2405\u20132412. https:\/\/doi.org\/10.2147\/DDDT.S153719","journal-title":"Drug Des Devel Ther"},{"issue":"5","key":"11713_CR59","doi-asserted-by":"publisher","first-page":"422","DOI":"10.33263\/BRIAC135.422","volume":"13","author":"MA Manavi","year":"2022","unstructured":"Manavi MA (2022) Identification of some novel racetams as potential anti-convulsant agents: virtual screening, molecular docking, and ADMET study. Biointerface Res Appl Chem 13(5):422. https:\/\/doi.org\/10.33263\/BRIAC135.422","journal-title":"Biointerface Res Appl Chem"},{"key":"11713_CR60","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/BF02976244","volume":"19","author":"HJ Kim","year":"1996","unstructured":"Kim HJ, Han YH, Chung SJ, Lee MH, Shim CK (1996) Pharmacokinetics of talniflumate, a prodrug of niflumic acid, following oral administration to man. Arch Pharm Res 19:297\u2013301. https:\/\/doi.org\/10.1007\/BF02976244","journal-title":"Arch Pharm Res"},{"key":"11713_CR61","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/BF00560259","volume":"14","author":"F Andreasen","year":"1978","unstructured":"Andreasen F, Elsborg L, Husted S, Thomsen O (1978) Pharmacokinetics of sulfadiazine and trimethoprim in man. Eur J Clin Pharmacol 14:57\u201367. https:\/\/doi.org\/10.1007\/BF00560259","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"11713_CR62","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1186\/s12859-017-1934-z","volume":"18","author":"CT Rueden","year":"2017","unstructured":"Rueden CT, Schindelin J, Hiner MC, DeZonia BE, Walter AE, Arena ET, Eliceiri KW (2017) ImageJ2: ImageJ for the next generation of scientific image data. BMC Bioinformatics 18(1):529. https:\/\/doi.org\/10.1186\/s12859-017-1934-z","journal-title":"BMC Bioinformatics"},{"issue":"1","key":"11713_CR63","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1083\/jcb.200103134","volume":"154","author":"PA Marignani","year":"2001","unstructured":"Marignani PA, Carpenter CL (2001) Vav2 is required for cell spreading. J Cell Biol 154(1):177\u2013186. https:\/\/doi.org\/10.1083\/jcb.200103134","journal-title":"J Cell Biol"}],"container-title":["Molecular Diversity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11030-026-11713-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11030-026-11713-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11030-026-11713-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T14:15:33Z","timestamp":1789827333000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11030-026-11713-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,19]]},"references-count":63,"alternative-id":["11713"],"URL":"https:\/\/doi.org\/10.1007\/s11030-026-11713-0","relation":{},"ISSN":["1573-501X"],"issn-type":[{"value":"1573-501X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,19]]},"assertion":[{"value":"8 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}